Xequel Bio is a clinical stage biopharmaceutical company transforming its proprietary alpha-connexin carboxyl-terminal 1 (aCT1) peptide technology platform to develop drugs that will revolutionize the way the body responds to injury.
Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential.
This is our Xequel.
“At Xequel, we combine the power of leadership with our personal conviction to pioneer meaningful science that ultimately impacts doctors and patients.”
– Jerry St. Peter, CEO & Board Director
Xequel Bio’s alpha-connexin carboxyl-terminal 1 (aCT1) is a new chemical entity that restores gap junction integrity, enables intercellular communication, and regulates inflammation at the injury site, culminating in a healthy injury response. aCT1 is an unprecedented solution that promotes healing by rebuilding healthy tissue through accelerated re-epithelialization.
Our proprietary aCT1 technology platform has extensive preclinical and clinical research to support multiple unique applications and formulations in Dermatology, Ophthalmology, and Pulmonology.
We are committed to developing treatments that address unmet medical needs and revolutionize the way the body responds to injury.
Granexin® Gel is a topical formulation of aCT1 developed to address unmet clinical needs within the field of dermatology and wound healing.
iNexin™ Eye Drops is an innovative formulation of aCT1 developed to address unmet needs within the field of ophthalmology focusing on corneal and retinal diseases.
aCT1 inhalation solution is a preclinical formulation being developed to address unmet needs within the field of pulmonology focusing on acute injury.
– Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury – – Xequel Launches New
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 –
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance
1501 Belle Isle Avenue
Suite 220
Mount Pleasant, South Carolina 29464
843.388.3276